OBJECTIVE
Thymomas, a rare malignancy, are located in 95% anterior mediastinum. They are associated with paraneoplastic syndromes, especially myasthenia graves. Although many classifications are used considering the depth of invasion, presence of metastasis, predominant cell type, or immunohistochemical properties in staging, Masoaka classification is commonly used. Surgery is the most effective method in the treatment of thymoma, and neoadjuvant chemotherapy is recommended in advanced stages (III-IV). Adjuvant radiotherapy has proven efficacy in advanced and inoperable patients. In this study, we aimed to evaluate treatment outcomes and factors affecting prognosis in thymoma patients.